The effect of high-dose fluticasone propionate and budesonide on lung function and asthma exacerbations in patients with severe asthma

Respiratory Medicine

Volumn 93, Issue 9, 1999, Pages 613-620

  Heinig, J H ^a   Boulet, L P ^b   Croonenborghs, L ^c   Mollers M J ^d  

^a Rigshospitalet   (Denmark)

^b LAVAL UNIVERSITY   (Canada)

^c Sint Augustinuskliniek   (Belgium)

^d Ziekenhuiscentrum Apeldoorn   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE;

ABSENTEEISM; ADULT; AGED; ARTICLE; ASTHMA; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMMUNOPATHOLOGY; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PEAK EXPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE;

EID: 0032848567     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(99)90100-2     Document Type: Article

References (32)

1. Dahl R, Lundback B, Malo L, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993; 104: 1352-1358.
2. Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg per day with inhaled beclomethasone dipropionate 400 μg per day in mild and moderate asthma. Arch Dis Child 1993; 69: 206-211.
3. Barnes N, Hallett C, Harris TAJ. Fluticasone propionate (FP) in asthma: a meta-analysis of efficacy and systemic activity of clinically recommended doses compared with budesonide (BUD) and beclomethasone dipropionate (BDP). Respir Med 1998; 92: 95-104.
4. Langdon CG, Capsey LJ. Fluticasone propionate and budesonide in adult asthmatics: a comparison using dry-powder inhaler devices. Br J Clin Res 1994; 5: 85-89.
5. ® inhaler in paediatric patients. Br J Clin Pract 1997; 51: 147-153.
6. Langdon CG, Thompson J, on behalf of the UK Study Group. A multicentre study to compare the efficacy and safety of inhaled fluticasone propionate and budesonide via metered-dose inhalers in adults with mild-to-moderate asthma. Br J Clin Res 1994; 5: 73-84.
7. Connolly A, on behalf of the UK Study Group. A comparison of fluticasone propionate 100 micrograms twice daily with budesonide 200 micrograms twice daily via their respective powder devices in the treatment of mild asthma. Eur J Clin Res 1995; 7: 15-29.
8. ® inhaler in adult asthmatics. J Allergy Clin Immunol 1996; 97: 249.
9. ® in the treatment of steroidnaive asthmatics. Am J Respir Crit Care Med 1996; 153: A338.
10. Barnes NC, Marane G, Di Maria GU, Visser S, Uiarna I, Payne SL. A comparison of fluticasone propionate 1 mg daily with beclomethasone propionate 2 mg daily in the treatment of severe asthma. Eur Respir J 1995;8:877-885.
11. Ringdal N, Swinburn P, Backman R, et al. A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: A clinical evaluation. Mediators Inflamm 1996; 5: 382-389.
12. Leblanc P, Mink S, Keistinen T, Saarelainen PA, Ringdal N, Payne SL. A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma. Allergy 1994; 49: 380-385.
13. Pauwels RA, Demedts MG, Yernault JC, Geusens P, Roosens WA. Comparison of long-term safety and efficacy of fluticasone propionate and beclomethasone dipropionate in combination with salmeterol in patients with moderate to severe asthma. Am J Respir Crit Care Med 1995; 151: A276.
14. -1) administered by pressurized inhaler. Respir Med 1993; 87: 609-620.
15. Bootsma GP, Dekhuijzen PNR, Festen J, van Herwaarden CLA. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness. Am J Respir Crit Care Med 1995; 151: A275.
16. Fabbri L, Burge PS, Croonenburgh F, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993; 48: 817-823.
17. Ayres JG, Bateman ED, Lundback B, Harris TA. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1·6 :mg daily, in patients with chronic severe asthma. International Study Group. Eur Respir J 1995; 8: 579-586.
18. Lundback B, Dahl R, De Jonghe M, et al. A comparison of fluticasone propionate when delivered by either the metered-dose inhaler or the Diskhaler inhaler in the treatment of mild-to-moderate asthma. Eur J Clin Res 1994; 5: 11-19.
19. Dahl R. The safety and efficacy of fluticasone propionate 200 μg daily given via the Diskhaler inhaler as compared with the pressurised metered dose inhaler in adult asthma. Clin Exp Allergy 1993; 23 (Suppl. 1):81.
20. Bousquet J, Tisserand B, Medley HV. Double-blind parallel-group study to compare the long term clinical efficacy and safety of two different methods of administering inhaled fluticasone propionate in chronic severe asthmatic patients. Eur Respir J 1995; 8 (Suppl. 19): 427S.
21. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69: 130-133.
22. Berend N. A six month comparison of the efficacy of high dose fluticasone propionate with beclomethasone dipropionate and budesonide in adults with severe asthma. Eur Respir J 1997; 10 (Suppl. 25): 105S.
23. Boe J, Bakke P. Rodolen T, et al. High dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic pituitary adrenal axis. Eur Respir J 1994; 7: 2179-2184.
24. Levy ML, Stevenson IC, Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax 1996; 51: 1087-1092.
25. Noonan M, Berger W, Chervinsky P, et al. Fluticasone propionate via Diskus is effective in reducing oral prednisone requirements in severe asthmatic patients. Am J Respir Crit Care Med 1997; 155: A349.
26. Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med 1995; 152: 1467-1473.
27. Fuller RW, Hallett C, Dahl R. Editorial: assessing equivalence of inhaled drugs. Respir Med 1995; 89: 525-527.
28. Barnes PJ. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J Allergy Clin Immunol 1998; 101: S427-S433.
29. Falcoz C, Mackie AE, Moss J, et al. Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus after repeat doses in healthy subjects and asthmatic patients. J Allergy Clin Immunol 1997; 99: S505.
30. Thorsson L, Edsbacker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler, P-MDI. Eur Respir J 1994; 7: 1839-1844.
31. Ganderton D. General factors influencing drug delivery to the lung. Respir Med 1997; 91 (Suppl. A): 13-16.
32. Fuller RW, Sharma RK, Cripps A. Letter to the editor. Eur Respir J 1995; 8: 2194.